The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study
- Abstract
- We aimed to evaluate the current nationwide trend, efficacy, safety, and quality of life (QoL) profiles of hormone treatment in real-world practice settings for prostate cancer (PCa) patients in Korea. A total of 292 men with any biopsy-proven PCa (TanyNanyMany) from 12 institutions in Korea were included in this multi-institutional, observational study of prospectively collected data. All luteinizing hormone-releasing hormone (LHRH) agonists were allowed to be investigational drugs. Efficacy was defined as (1) the rate of castration (serum testosterone ≤50 ng dl(-1)) at 4-week visit and (2) breakthrough (serum testosterone >50 ng dl(-1) after castration). Safety assessments included routine examinations for potential adverse events, laboratory tests, blood pressure, body weight, and bone mineral density (BMD, at baseline and at the last follow-up visit). QoL was assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26). The most common initial therapeutic regimen was LHRH agonist with anti-androgen (78.0%), and the most commonly used LHRH agonist for combination and monotherapy was leuprolide (64.0% for combination and 58.0% for monotherapy). The castration and breakthrough rates were 78.4% and 6.6%, respectively. The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment. In addition, the mean BMD T-score was significantly lower at the last follow-up (mean: -1.950) compared to baseline (mean: -0.195). The mean total EPIC-26 score decreased from 84.8 (standard deviation [s.d.]: 12.2) to 78.3 (s.d.: 8.1), with significant deterioration only in the urinary domain (mean: 23.5 at baseline and 21.9 at the 4-week visit). These findings demonstrate the nationwide trend of current practice settings in hormone treatment for PCa in Korea.
- All Author(s)
- J. K. Kim
; J. J. Kim
; T. W. Gang
; T. K. Kwon
; H. S. Kim
; S. C. Park
; J. S. Park
; J. Y. Park
; S. J. Yoon
; Y. S. Jeon
; J. S. Cho
; K. J. Joo
; S. H. Hong
; S. S. Byun
- Issued Date
- 2019
- Type
- Article
- Keyword
- efficacy; hormonal treatment; Korean population; prostate cancer; safety; trend
- Publisher
- Asian Society of Andrology
- ISSN
- 1008-682X
- Citation Title
- Asian Journal of Andrology
- Citation Volume
- 21
- Citation Number
- 2
- Citation Start Page
- 115
- Citation End Page
- 120
- Language(ISO)
- eng
- DOI
- 10.4103/aja.aja_95_18
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/1540
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.